Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by stefchillon Mar 04, 2017 10:49am
133 Views
Post# 25931410

RE:RE:tech watch!!!

RE:RE:tech watch!!!Also this note seems new to me.....

DIAGNOS has spreadsheets with analysts in the US, at Medicaid and Medicare, that show the savings simply from preventing diabetics going blind, forget everything else that DIAGNOS can help combat, the Company can save in the state of Florida alone over $6 billion over the next 20 years (Note: DIAGNOS is in proposal stage with Florida at the moment). It is expected that in 2018 Medicaid and Medicare will be establishing new guidelines for screening and are expected to be spending substantial amounts on screening programs. Government involvement with DIAGNOS is the big prize for shareholders; when key news is announced, we anticipate it will act as a major catalyst that will supplant all current projections and cause a dramatic upside revaluation in share price, well above what is being discussed here today.

Bullboard Posts